Compound for degrading c-Src kinase as well as pharmaceutical composition and application thereof
By designing a selective c-Src kinase degrader, using the linking groups of the compound and the E3 ubiquitin ligase ligand, the problems of poor selectivity and off-target effects in the prior art are solved, and the c-Src is achieved Effective degradation of kinases and improvement of cancer treatment effects.
Patent Information
- Application Number
- CN202310658621.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
The existing c-Src kinase degrading agents are based on pankinase inhibitor design, and have adverse reactions that may result from poor selectivity and off-target effects, making it difficult to effectively treat c-Src-related diseases, especially cancer.
A compound was designed to link the E3 ubiquitin ligase ligand through selective c-Src kinase ligand, and the compounds formed can selectively degrade c-Src kinase and reduce the toxic side effects caused by off-targeting. Specific compounds such as DC-Srci -6668 and its derivative T2 have improved the binding inhibitory activity and selectivity of c-Src kinase through eutectic structure optimization.
The selective degradation of c-Src kinase was achieved, reducing the toxic side effects caused by off-target effects, and significantly improving the effect on cancer treatment, especially in the inhibition of proliferation of triple-negative breast cancer and thyroid cancer cells. active.
Smart Images

Figure CN119080869A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a class of compounds represented by formula (I) and pharmaceutical compositions thereof, and their use in preparing drugs for treating, preventing and / or improving diseases associated with c-Src kinase, especially cancer. Background Art
[0002] c-Src kinase is a non-receptor tyrosine kinase. The Src kinase family (SFKs) has 11 members, among which Src, Fyn, Yes and Fgr are closely related and belong to class I enzymes; Blk, Hck, Lck and Lyn are class II enzymes; Frk, Srm and Brk are class III enzymes because they are distantly related to the first two groups of enzymes. Src, Fyn and Yes are expressed in all cell types, Blk, Fgr, Hck, Lck and Lyn are mainly present in hematopoietic cells, Srm is mainly present in keratinocytes, Frk is mainly present in bladder, brain, breast, colon and lymphocytes, and Brk is mainly present in colon, prostate and small intestine. Src protein is ubiquitously expressed in vertebrate cells, and the protein expression level in brain cells, osteoclasts and platelets is 5-200 times higher than that in most other cells. In fibroblasts, Src can interact with various growth factors, integrins and G protein-coupled receptors to mediate cell signal transduction.
[0003] The structures of the members of the Src kinase family are similar, from the nitrogen end to the carbon end, with a myristoyl group, a unique domain, an SH 3 domain, one SH 2 c-Src kinase has a structural domain and a protein tyrosine kinase domain SH1. Once activated, c-Src kinase can regulate multiple complex downstream signaling pathways, including RAS / MAPK, PI3K / AKT and STAT pathways, and participate in the regulation of physiological processes such as proliferation, differentiation, survival, movement and angiogenesis. Therefore, the abnormal activation of c-Src has a significant promoting effect on multiple processes of tumor development, such as cell proliferation, cell adhesion, cell migration and invasion, angiogenesis and tumor metastasis. At present, studies have found that overexpression or overactivation of c-Src is widely present in a variety of malignant tumors, including colorectal cancer, breast cancer, prostate cancer, pancreatic cancer, head and neck cancer, lung cancer, glioma and melanoma, which shows that c-Src kinase is a potential target for cancer treatment.
[0004] PROTAC (proteolysis-targeting chimeras) is a drug development technology that uses the ubiquitin-proteasome system (UPS) to degrade target proteins. PROTAC is a chemical molecule with different ligands at both ends, one end is a ligand that binds to E3 ubiquitin ligase, and the other end is a ligand that binds to intracellular proteins. The two ligands are then connected by a linker. Such a chemical molecule can bind to both E3 ubiquitin ligase and intracellular proteins, and achieves polyubiquitination of the target protein by recruiting the target protein to the vicinity of the E3 ubiquitin ligase, and finally is degraded by the proteasome. The existing PROTAC degrader is a c-Src / IGF-1R dual-effect degrader designed based on a pan-kinase inhibitor ligand, and c-Src has a different physiological function from IGF-1R (Insulin-like growth factor1 receptor). The off-target effect produced by the dual-effect degradation may lead to adverse reactions. Summary of the invention
[0005] In order to overcome the problems existing in the prior art, one of the objects of the present invention is to provide a compound represented by formula (I):
[0006]
[0007] A second object of the present invention is to provide a c-Src kinase degrading agent containing the compound represented by the above formula (I).
[0008] A third object of the present invention is to provide a pharmaceutical composition containing the compound represented by the above formula (I).
[0009] A fourth object of the present invention is to provide a use of the compound represented by the above formula (I) and the above pharmaceutical composition in the preparation of drugs for preventing, treating and / or improving diseases related to c-Src kinase, especially cancer.
[0010] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0011] The first aspect of the present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof;
[0012]
[0013] Wherein, the linking group is -(L 1 ) n -(L 2 ) n -(L3 ) n -(L 4 ) n -(L 5 ) n -;
[0014] L 1 , L 2 , L 3 , L 4 , L 5 Each independently selected from: -CR L 2 -、-O-、-S-、-NR L -、 -N=、=N-、-CR L =CR L -、-C≡C-、C 3-8 Cyclic hydrocarbon group, 3-8 membered heterocyclic hydrocarbon group, 4-8 membered cyclic ketone, 4-8 membered cyclic lactam, P(=O)R L 、P(=O)OR L ;
[0015] Each n is independently selected from any integer between 0 and 20, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20;
[0016] Each R L are each independently selected from H, halogen, -OH, -NH 2 ,-SH,C 1-8 Alkyl, C 2-8 Olefin group, C 2-8 Alkyne, -O(C 1-8 Alkyl), -S(C 1-8 Alkyl), -NH(C 1-8 Alkyl), -N(C 1-8 alkyl) 2 , C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, -O(C 3-8 Cycloalkyl), -S(C 3-8 Cycloalkyl), -NH(C 3-8 Cycloalkyl), -N(C 3-8 Cycloalkyl) 2 、-O(3-8 membered heterocyclic hydrocarbon group), -S(3-8 membered heterocyclic hydrocarbon group), -NH(3-8 membered heterocyclic hydrocarbon group), -N(C3-8 membered heterocyclic hydrocarbon group) 2 、-N(3-8 membered heterocyclic hydrocarbon group)(C 3-8 Cyclic hydrocarbon group), -N(3-8 membered heterocyclic hydrocarbon group)(C 1-8Alkyl), -N(C 1-8 Alkyl)(C 3-8 wherein the heterocyclic hydrocarbon group contains 1-4, preferably 1-3, more preferably 1-2 heteroatoms selected from N, O or S in the ring;
[0017] The E3 ubiquitin ligase ligand is selected from:
[0018] In a specific embodiment, in formula (I), the linking group is -(L 1 ) n -(L 2 ) n -(L 3 ) n -(L 4 ) n -(L 5 ) n -;
[0019] Among them, L 1 , L 2 , L 3 , L 4 , L 5 Each independently selected from: -CR L 2 -、-O-、-S-、-NR L -、 -N=、=N-、-CR L =CR L -、-C≡C-、P(=O)R L 、P(=O)OR L ;
[0020] Each n is independently selected from any integer between 0 and 10, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;
[0021] Each RL is independently selected from H, halogen, -OH, -NH 2 ,-SH,C 1-8 Alkyl, C 2-8 Olefin group, C 2-8 Alkyne, -O(C 1-8 Alkyl), -S(C 1-8 Alkyl), -NH(C 1-8 Alkyl), -N(C 1-8 alkyl) 2 .
[0022] Preferably, the linking group is selected from -(CR L 2 ) n -、-(CRL 2 ) n -CO-、-CO-(CR L 2 ) n -、-(CR L 2 ) n -CONR L -、-NR L CO-(CR L 2 ) n -、-(CR L 2 ) n CONR L (CR L 2 ) n -、-(CR L 2 ) n NR L CO(CR L 2 ) n -、-(CR L 2 ) n CONR L (CR L 2 ) n CO-、-CO(CR L 2 ) n CONR L (CR L 2 ) n -、-(CR L 2 ) n -O-、-O-(CR L 2 ) n -、-(CR L 2 -O) n -(CR L 2 ) n -、-(CR L 2 ) n -S-、-S-(CR L 2 ) n -、-NR L -(CR L 2 ) m -、-(CRL 2 ) n -NR L -; More preferably, the linking group is selected from -(CR L 2 ) n -、-(CR L 2 ) n -CO-、-CO-(CR L 2 ) n -、-(CR L 2 ) n CONR L (CR L 2 ) n -、-(CR L 2 ) n NR L CO(CR L 2 ) n -、-(CR L 2 ) n CONR L (CR L 2 ) n CO-、-CO(CR L 2 ) n CONR L (CR L 2 ) n -;
[0023] wherein each n is independently selected from any integer between 1 and 8, preferably any integer between 2 and 8, and more preferably any integer between 3 and 8;
[0024] Each R L are each independently selected from H, halogen, -OH, -NH 2 ,-SH,C 1-8 Alkyl; preferably H, halogen, -OH, -NH 2 ,-SH,C 1-3 Alkyl; more preferably H,
[0025] E3 ubiquitin ligase ligands are described above.
[0026] In a specific embodiment, the compound represented by formula (I) is selected from the following structures:
[0027]
[0028] The second aspect of the present invention provides a c-Src kinase degrading agent, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof.
[0029] The third aspect of the present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof; and optionally, a pharmaceutically acceptable carrier.
[0030] The compound of the present invention or its composition can be administered orally or parenterally to the patient in the form of conventional preparations, such as capsules, microcapsules, tablets, granules, powders, lozenges, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions. Suitable preparations can be prepared by commonly used methods using conventional organic or inorganic additives, such as excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), binders (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose or starch), disintegrants (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low-substituted hydroxypropylcellulose, sodium bicarbonate). , calcium phosphate or calcium citrate), lubricants (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), flavoring agents (e.g., citric acid, menthol, glycine or orange powder), preservatives (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), stabilizers (e.g., citric acid, sodium citrate or acetic acid), suspending agents (e.g., methylcellulose, polyvinylpyrrolidone or aluminum stearate), dispersants (e.g., hydroxypropyl methylcellulose), diluents (e.g., water) and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol).
[0031] The dosage regimen can be adjusted to provide the best desired response. For example, when the drug is administered in the form of an injection, a single push, a bolus injection and / or a continuous infusion, etc., can be administered. For example, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the treatment situation, or the dose can be proportionally reduced or increased according to the treatment situation. It should be noted that the dosage value can vary with the type and severity of the condition to be alleviated, and can include single or multiple doses. Generally, the dosage of treatment varies, depending on the considerations, such as: the age, sex and general health of the patient to be treated; the frequency of treatment and the nature of the desired effect; the degree of tissue damage; the duration of symptoms; and other variables that can be adjusted by individual physicians. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual needs and the professional judgment of the person administering the composition or supervising the administration of the composition. The dosage and administration regimen of the pharmaceutical composition can be easily determined by a person of ordinary skill in the clinical field. For example, the compound of the present invention or its composition can be administered once every 7 days in divided doses 4 times a day, and the dosage can be, for example, 0.01 to 1000 mg / time. The required dose can be administered once or multiple times to obtain the desired result. The pharmaceutical composition according to the present invention can also be provided in unit dosage form.
[0032] The fourth aspect of the present invention provides the use of the compound represented by the above formula (I) or its pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative, or the above pharmaceutical composition in the preparation of a drug for treating, preventing and / or ameliorating diseases associated with c-Src kinase.
[0033] Another aspect of the present invention provides the use of the compound represented by the above formula (I) or its pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative, or the above pharmaceutical composition in the preparation of drugs for treating, preventing and / or ameliorating cancer.
[0034] In a specific embodiment, the above-mentioned diseases associated with c-Src kinase include: cancer, cardiovascular disease, neurodegenerative disease, malaria, AIDS, gout, diabetes, renal failure, and chronic lung disease.
[0035] In the present invention, cancer includes colon cancer, diffuse large B-cell lymphoma, follicular lymphoma, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast cancer, bile duct and gallbladder cancer, bladder cancer, brain tumor, neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancer, parathyroid tumor, uterine tumor and soft tissue sarcoma. In particular, cancer includes breast cancer (especially triple-negative breast cancer) and thyroid cancer.
[0036] The definitions of terms in this invention are as follows:
[0037] As used herein, "halogen" may be fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.
[0038] As used herein, the term "C 1-8 "Alkyl" refers to a straight or branched chain alkyl group having 1 to 8 carbon atoms, for example, "C 1-6 Alkyl", "C 1-4 Alkyl", "C 1-3 Specific examples thereof may include methyl, ethyl, propyl, n-propyl, isopropyl, butyl, n-butyl, isobutyl, tert-butyl, 1-methyl-butyl, 1-ethyl-butyl, pentyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, tert-pentyl, hexyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 4-methyl-2-pentyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like, but are not limited thereto.
[0039] As used herein, “C 2-8 "Alkenyl" refers to a linear or branched monovalent hydrocarbon group having 2 to 8 carbon atoms and containing at least one double bond, for example, "C 2-6 Olefin group", "C 2-4 Specific examples thereof may include vinyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, isopentenyl, hexenyl, heptenyl, octenyl, and the like.
[0040] As used herein, “C 2-8 "Alkynyl" refers to a linear or branched monovalent hydrocarbon group having 2 to 8 carbon atoms and containing at least one triple bond, for example, "C 2-6 Alkyne", "C 2-4 Specific examples thereof may include ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, pentynyl, isopentenyl, hexynyl, heptynyl, octynyl, and the like.
[0041] As used herein, “C3-8 "Cycloalkyl" refers to a monocyclic or polycyclic alicyclic hydrocarbon group or aromatic hydrocarbon group having 3 to 8 ring carbon atoms, wherein the alicyclic hydrocarbon group may contain no or at least one unsaturated bond (not completely saturated), for example, "C 3-7 Cycloalkyl", "C 4-6 Cycloalkyl", "C 5-6 In the present invention, the cycloalkyl group is preferably a cycloalkyl group. 3-8 Specific examples of the cycloalkyl group may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, phenyl, and the like.
[0042] As used herein, "3-8 membered heterocyclic hydrocarbon group" is a "C 3-8 "Cycloalkyl", provided that 1-4 ring carbons are replaced by heteroatoms selected from N, O or S, and the present invention is preferably C3-8 heterocycloalkyl. Specific examples of 3-8 membered heterocycloalkyl can include oxirane, aziridine, azetidinyl, oxetanyl, azopentyl (pyrrolidinyl), tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl, pyrrolidin-2-one, imidazolonyl, piperidine 1,3-oxazinyl, hexahydropyranyl, piperazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, isothiazolyl, oxazolyl, pyridyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidinyl, oxazinyl, oxadiazinyl, etc. As used herein, in the present invention, isotopically labeled derivatives include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, and fluorine, for example, 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 35 S and 18 F. Compounds of the present invention that contain the aforementioned isotopes and / or other isotopes of other atoms are within the scope of the present invention.
[0043] As used herein, in the present invention, pharmaceutically acceptable salts are: salts of suitable compounds of the present invention with organic acids, organic bases, inorganic acids, and inorganic bases, such as: hydrochloric acid, trifluoroacetic acid, sulfuric acid, acetic acid, phosphoric acid, citric acid, lactic acid, fumaric acid, maleic acid, methanesulfonic acid, nitric acid, hydrobromic acid, tartaric acid, ethanolamine, diethanolamine, N-ethylethanolamine, N-methylethanolamine, triethanolamine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylaminoisopropanol, 2-amino-2-methylpropane, triisopropanolamine, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, dimethyldodecylamine; triethylaminebenzylamine, dibenzylamine, N-methylpiperazine, 4-methylcyclohexylamine, N-methylmorpholine, methylamine, ethylamine, alkaline earth metals, alkali metals, aluminum, and transition metal salts. These salts can be prepared from the compound represented by formula (I) by known salt-forming methods. Preferably, the pharmaceutically acceptable salt is trifluoroacetate.
[0044] The compounds provided by the present invention also include prodrug forms, which refer to compounds that are rapidly converted in vivo to the parent compound of the above formula and are converted to the compounds of the present invention by chemical or biochemical methods in an in vivo or in vitro environment, such as by hydrolysis in the blood.
[0045] The compounds of the present invention can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are also encompassed within the scope of the present invention.
[0046] The compounds of the present invention exist in geometric isomers and stereoisomers, such as cis-trans isomers, enantiomers, diastereomers, and racemic mixtures and other mixtures thereof, and all such mixtures are within the scope of the present invention.
[0047] As used herein, the term "enantiomer" refers to stereoisomers that are mirror images of one another.
[0048] As used herein, the term "diastereomer" refers to stereoisomers that have two or more chiral centers and are not mirror images of each other.
[0049] As used herein, the term "cis-trans isomers" refers to configurations in which a double bond or a single bond of a ring-forming carbon atom in a molecule cannot rotate freely.
[0050] Unless otherwise specified, the key is a solid wedge. and dotted wedge key Indicates the absolute configuration of a stereocenter.
[0051] Stereoisomers of the compounds of the invention may be prepared by chiral synthesis or chiral reagents or other conventional techniques.
[0052] Beneficial effects of the present invention:
[0053] The compound in formula (I) of the present invention is a compound composed of a selective c-Src kinase ligand linked to an E3 ubiquitin ligase ligand, which can selectively degrade c-Src kinase, be used for cancer treatment, and reduce toxic side effects caused by off-target effects. DETAILED DESCRIPTION
[0054] In the previous study, the inventors screened a lead compound DC-Srci-6668 (Zhang, H. et al. J. Med. Chem. 2021, 64, 20, 15111-15125) through covalent docking virtual screening and biochemical experimental verification, and analyzed the co-crystal structure of its complex with c-Src kinase. The results showed that the compound binds to c-Src kinase in the inactive state and inhibits the active IC 50 The inhibitory activity of compound T2 after replacing the α-chloroamide group of DC-Srci-6668 with an acrylamide group and replacing the para-fluorine atom of the benzene ring with tetrafluoroethylene at the ortho-meta-position was the best, with an IC 50 The inhibitory effect of compound T2 on c-Src kinase was as high as 20 nM, and the kinase selectivity was good. The study found that compound T2 had weak binding to multiple kinase targets except c-Src kinase (for example, for targets VEGFR1 / 2 / 3, FGFR1 / 2 / 3 / 4, EGFR, PDGFRα / β, ErbB2 / 4, Ret, Flt-3, IGF1R, IR, Abl, EPH-A2 / B2, ACK1, c-Kit, CSF1R and BTK, the inhibition rate of compound T2 at a concentration of 10 uM was less than 50%). Based on the structural information of compound T2 and co-crystals of such skeleton derivatives and c-Src kinase complexes, the inventors designed and synthesized a series of c-Src kinase degraders to overcome the shortcomings of the current c-Src kinase degraders designed based on pan-kinase inhibitor ligands, such as poor selectivity and off-target effects that may lead to adverse reactions.
[0055]
[0056] The specific implementation of the present invention is further described in detail below in conjunction with examples, but the implementation and protection of the present invention are not limited thereto. It should be noted that if there are processes that are not particularly described in detail below, they can be implemented or understood by those skilled in the art with reference to the prior art. If the manufacturer of the reagents or instruments used is not indicated, they are deemed to be conventional products that can be purchased commercially.
[0057] Compound Synthesis Examples
[0058] Route: Synthesis route of compounds SV1-SV5, SC1-SC3
[0059]
[0060] The reagents and reaction conditions used in the above route are: (a) ethyl formate, TEA, 80°C; (b) phosphorus oxychloride, DCM, TEA, 0°C; (c) MeOH, room temperature; (d) trifluoroacetic acid, DCM, room temperature; (e) HATU reagent, DIPEA, DMF, 25°C.
[0061] The intermediates V1-V5 in the above route were prepared by the synthesis method reported in Wang, M. et.al. J. Med. Chem. 2020, 63, 7510-7528 (Scheme 3 on page 7516); C1-C3 were prepared by the synthesis method reported in Cheng, J. et.al. J. Med. Chem. 2020, 63, 7892-7905 (Schemel on page 7894).
[0062]
[0063] Preparation of N-cyclopentanecarboxamide (Intermediate Int-1):
[0064] Cyclopentylamine 1 (10.0 g, 117.6 mmol, 1.0 equivalent), triethylamine (23.8 g, 235.2 mmol, 17.7 mL, 2.0 equivalent) and ethyl formate (23.5 g, 317.3 mmol, 32.7 mL, 5.0 equivalent) were added to a 250 mL round-bottom flask, and the mixture was stirred at 80°C for 16 hours. After the reaction was completed as monitored by TLC, the solvent was removed by distillation under reduced pressure, 50 mL of dichloromethane was added to dissolve the mixture, the residual cyclopentylamine was washed with dilute hydrochloric acid (20 mL × 3), and the excess hydrochloric acid was neutralized with saturated sodium bicarbonate solution (20 mL × 3), and finally washed with water, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure to obtain 10.6 g of intermediate Int-1 with a yield of 80%, as a yellow oil. 1H NMR (500 MHz, DMSO-d 6 )δ8.07-7.93(m, 1H), 7.89(s, 1H), 4.10-3.95(m, 1H), 1.80-1.73(m, 2H), 1.63-1.56(m, 2H), 1.52-1.43(m, 2H), 1.38-1.30(m, 2H).
[0065] Preparation of N-cyclopentyl isonitrile (intermediate Int-2)
[0066] Under argon protection, the intermediate Int-1 (10.6 g, 94.1 mmol, 1.0 equivalent) obtained in the first step and triethylamine (85.8 g, 846.9 mmol, 78.9 mL, 9.0 equivalent) were added to a 500 mL round-bottom flask, and 200 mL of anhydrous dichloromethane was added and stirred thoroughly to dissolve. After cooling the reaction system in an ice bath, phosphorus oxychloride (43.3 g, 282.3 mmol, 26.3 mL, 3.0 equivalents) was slowly added dropwise to the system. After reacting in the ice bath for 2 hours, the system was transferred to room temperature for reaction for 2 hours. After the reaction of intermediate 2 was completed, the reaction system was slowly poured into a saturated sodium bicarbonate solution (500 mL) in an ice bath to quench, and the aqueous phase and the organic phase were separated. The aqueous phase was extracted with dichloromethane (100 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure to obtain 3.6 g of intermediate Int-2 with a yield of 40%, as a brown liquid. 1 H NMR: (500MHz, CDCl3) δ3.90 (m, 1H), 1.97-1.85 (m, 4H), 1.88-1.75 (m, 2H), 1.71-1.55 (m, 2H).
[0067] Preparation of tert-butyl 5-(2-(cyclopentylamino)-2-oxo-1-(2,3,5,6-tetrafluorophenyl)ethyl)-6-oxooct-7-enoate (intermediate int-3)
[0068] 2,3,5,6-tetrafluorobenzaldehyde (178.0 mg, 1.0 mmol, 1.0 equivalent) and tert-butyl 4-aminobutyrate (159.2 mg, 1.0 mmol, 1.0 equivalent) and MeOH (8 mL) were added to a 10 mL round-bottom flask, and stirred at room temperature for 30 minutes to generate part of the imine, and then acrylic acid (72.0 mg, 1.0 mmol, 1.0 equivalent) was added to the reaction mixture, and cyclopentylisocyanate (95.0 mg, 1.0 mmol, 1.0 equivalent) was added after stirring and dissolving. The reaction mixture was stirred at room temperature overnight. After the reaction was complete as monitored by HPLC-MS, the mixture was distilled under reduced pressure to remove the solvent, and the final product was separated and purified by Flash column machine (gradient: ethyl acetate / petroleum ether = 5% to ethyl acetate / petroleum = 30%) to obtain 212 mg of light yellow oily liquid with a yield of 43%. 1 HNMR (500 MHz, DMSO-d 6)δ8.08 (d, J=7.0Hz, 1H), 8.02-7.94 (m, 1H), 6.79 (dd, J=16.5, 10.3Hz, 1H), 6.39 (s, 1H), 6.26 (dd, J=16.5, 2.4Hz, 1H), 5.80 (dd, J=10.3, 2.4Hz, 1 H), 4.06-3.98 (m, 2H), 3.54-3.47 (m, 1H), 3.23-3.15 (m, 1H), 2.11-2.06 (m, 3H), 1.99 (s, 1H), 1.81-1.74 (m, 2H), 1.60-1.45 (m, 6H), 1.36 (s, 9H).
[0069] General method for the synthesis of compounds SV1-SV5, SC1-SC3:
[0070] In a 10 mL round-bottom flask, the intermediate int-3 (24.5 mg, 0.05 mmol, 1.0 equivalent) was added and dissolved in DCM (2 mL), and trifluoroacetic acid (11.4 mg, 0.1 mmol, 2.0 equivalent) was added and stirred at room temperature for 5 hours. After the reaction was completed as monitored by HPLC-MS, the mixture was distilled under reduced pressure to remove the solvent, and DMF (2 mL) was added, followed by DIPEA (32.5 mg, 0.25 mmol, 5.0 equivalent), V1 (24. 3 mg, 0.05 mmol, 1.0 equiv) and HATU reagent (19.0 mg, 0.05 mmol, 1.0 equiv), react at room temperature overnight, add water to quench the reaction, distill the mixture under reduced pressure to remove DIPEA, and transfer it to a sample column, and further purify it by flash preparative chromatography (C18 silica gel column, acetonitrile and an aqueous solution containing 0.1% CF3COOH in a volume ratio of 5% to 100%) to obtain 6.9 mg of the final product SV-1-SV5, SC1-SC3.
[0071] Example 1: Preparation of Compound SV-1
[0072]
[0073] The compound (2S,4R)-1-((2S)-2-(4-(N-(2-(cyclopentylamino)-2-oxo-1-(2,3,5,6-tetrafluorophenyl)ethyl)acrylamide)butyrylamide)butylamino)-3,3-dimethylbutyryl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (SV-1) was obtained by reacting int-3 and V1 as reactants. 1H NMR (500MHz, DMSO) δ8.99 (s, 1H), 8.37 (d, J = 7.8Hz, 1H), 8.07 (d, J = 7.1Hz, 1H), 7.80-7.77 (m, 1H), 7.74-7.71 (m, 1H), 7.45-7.42 (m, 2 H), 7.40-7.37 (m, 2H), 6.77-6.89 (m, 2H), 6.39-6.36 (m, 1H), 6.28-6.23 (m, 1H), 5.81-5.78 (m, 1H), 4.92 (t, J=7.3Hz, 2H), 4.51 (d, J=9 .3Hz, 2H), 4.46-4.39(m, 2H), 4.32-4.25(m, 2H), 4.04-3.98(m, 2H), 3.63-3.58(m, 3H), 2.46(s, 3H), 2.28-2.21(m, 2H), 2.15-2.08(m , 2H), 2.04-1.98(m, 2H), 1.93-1.88(m, 2H), 1.83-1.73(m, 4H), 1.62-1.56(m, 2H), 1.52-1.44(m, 4H), 1.39-1.37(m, 2H), 0.93(s, 9H).
[0074] Example 2: Preparation of Compound SV-2
[0075]
[0076] Using int-3 and V2 as reactants, 7.3 mg of the final product SV-2 was prepared by the above general method. 1 H NMR (500 MHz, DMSO-d 6)δ8.99 (s, 1H), 8.37 (d, J = 7.8Hz, 1H), 8.07 (d, J = 7.1Hz, 1H), 7.80-7.77 (m, 1H), 7.74-7.71 (m, 1H), 7.45-7.42 (m, 2H), 7.40-7.37 (m, 2H) , 6.80 (dd, J=16.4, 10.3Hz, 2H), 6.39-6.36 (m, 1H), 6.28-6.23 (m, 1H), 5.81-5.78 (m, 1H), 5.14-5.05 (m, 1H), 4.92 (t, J=7.3Hz, 2H), 4.51 (d, J=9.3Hz, 2H), 4.46-4.39 (m, 2H), 4.32-4.25 (m, 2H), 4.04-3.98 (m, 2H), 3.63-3.58 (m, 3H), 2.46 (s, 3H), 2.28-2.21 (m, 2H), 2.15-2.0 8(m, 2H), 2.04-1.98(m, 2H), 1.93-1.88(m, 2H), 1.83-1.73(m, 4H), 1.62-1.56(m, 2H), 1.52-1.44(m, 5H), 1.39-1.37(m, 2H), 0.93(s, 9H).
[0077] Example 3: Preparation of Compound SV-3
[0078]
[0079] Using int-3 and V3 as reactants, 5.6 mg of the final product SV-3 was prepared by the above general method. 1H NMR (500MHz, DMSO) δ8.99 (s, 1H), 8.37 (d, J = 7.8Hz, 1H), 8.07 (d, J = 7.0Hz, 1H), 8.00-7.94 (m, 1H), 7.78 (d, J = 9.3Hz, 1H), 7.73-7.69 (m, 1H) , 7.44 (d, J=8.3Hz, 2H), 7.38 (d, J=8.3Hz, 2H), 6.80 (dd, J=16.5, 10.4Hz, 1H), 6.38 (s, 1H), 6.26 (dd, J=16.5, 2.3Hz, 1H), 5.83-5.78 (m, 1H), 4.92 (t, J=7.2Hz, 2H), 4.52 (d, J=9.3Hz, 2H), 4.42 (t, J=8.0Hz, 2H), 4.28 (s, 2H), 4.07-3.96 (m, 2H), 3.64-3.53 (m, 3H), 2.46 (s, 3H), 2.29-2 .20(m, 2H), 2.16-2.05(m, 2H), 2.05-1.97(m, 2H), 1.96-1.85(m, 3H), 1.86-1.70(m, 5H), 1.66-1.47(m, 8H), 1.39-1.37(m, 2H), 0.94(s, 9H).
[0080] Example 4: Preparation of Compound SV-4
[0081]
[0082] Using int-3 and V4 as reactants, 5.6 mg of the final product SV-3 was prepared by the above general method. 1H NMR (500MHz, DMSO) δ8.99 (s, 1H), 8.37 (d, J = 7.8Hz, 1H), 8.07 (d, J = 6.9Hz, 1H), 7.99-7.94 (m, 1H), 7.78 (d, J = 9.3Hz, 1H), 7.71 (s, 1H), 7 .44 (d, J=8.1Hz, 2H), 7.38 (d, J=8.1Hz, 2H), 6.79 (dd, J=16.5, 10.3Hz, 1H), 6.38 (s, 1H), 6.29-6.21 (m, 1H), 5.82-5.76 (m, 1H), 4.92 (t, J=7.3Hz, 2H), 4.52 (d, J=9.4Hz, 2H), 4.42 (t, J=8.0Hz, 2H), 4.28 (s, 2H), 4.05-3.97 (m, 2H), 3.64-3.59 (m, 4H), 2.46 (s, 3H), 2.32-2.20 (m, 2H), 2.16-2.06 (m, 2H), 2.05-1.96 (m, 2H), 1.94-1.88 (m, 2H), 1.84-1.71 (m, 4H), 1.54-1.41 (m, 7H), 1.40-1.30 (m, 8H), 0.93 (s, 9H).
[0083] Example 5: Preparation of Compound SV-5
[0084]
[0085] Using int-3 and V5 as reactants, 5.6 mg of the final product SV-3 was prepared by the above general method. 1H NMR (500MHz, DMSO) δ8.99 (s, 1H), 8.37 (d, J = 7.8Hz, 1H), 8.07 (d, J = 6.8Hz, 1H), 7.99-7.92 (m, 1H), 7.77 (d, J = 9.3Hz, 1H), 7.7 0 (s, 1H), 7.44 (d, J = 8.2Hz, 2H), 7.38 (d, J = 8.1Hz, 2H), 6.83-6.77 (m, 1H), 6.38 (s, 1H), 6.28-6.24 (m, 1H), 5.81-5.77 (m, 1H), 4.98-4.89 (m, 2H), 4.52 (d, J=9.4Hz, 2H), 4.44-4.38 (m, 2H), 4.28 (s, 2H), 4.06-3.98 (m, 2H), 3.66-3.59 (m, 4H), 2.46 (s, 3H) , 2.38-2.35(m, 1H), 2.23(s, 2H), 2.01(s, 2H), 1.91(s, 2H), 1.79(s, 4H), 1.64-1.46(m, 7H), 1.41-1.28(m, 10H), 0.94(s, 9H).
[0086] Example 6: Preparation of Compound SC-1
[0087]
[0088] Using int-3 and C1 as reactants, 2.5 mg of the final product SV-3 was prepared by the above general method. 1 H NMR (500MHz, DMSO) δ11.09 (s, 1H), 8.07 (d, J = 7.1Hz, 1H), 7.98-7.95 (m, 1H), 7.74 (s, 1H), 7.60-7.56 (m, 1H), 7.09 (d, J =8.5Hz, 1H), 7.02 (d, J = 7.2Hz, 1H), 6.79 (dd, J = 16.4, 10.3Hz, 1H), 6.55-6.52 (m, 1H), 6.38 (s, 1H), 6.26 (d, J = 16.3Hz, 1H), 5.80 (d, J=10.2Hz, 1H), 5.05 (dd, J=12.8, 5.4Hz, 1H), 4.02-3.99 (m, 1H), 3.52-3.43 (m, 2H), 3.18-3.10 (m, 2H), 3. 00(s, 2H), 2.92-2.86(m, 3H), 2.61(s, 2H), 2.07-1.98(m, 2H), 1.96-1.87(m, 3H), 1.61-1.54(m, 6H), 1.44-1.35(m, 6H).
[0089] Example 7: Preparation of Compound SC-2
[0090]
[0091] Using int-3 and C2 as reactants, 5.2 mg of the final product SV-3 was prepared by the above general method. 1 H NMR (500 MHz, CDCl 3 )δ8.47 (s, 1H), 7.55-7.50 (m, 1H), 7.14-7.09 (m, 2H), 6.89 (d, J=8.5Hz, 1H), 6.77 (s, 1H), 6.54-6 .35(m, 2H), 6.30-6.16(m, 2H), 5.91-5.67(m, 2H), 4.95-4.88(m, 1H), 4.23(s, 1H), 3.76-3.64(m, 1 H), 3.66-3.39(m, 2H), 3.32-3.25(m, 2H), 3.25-3.16(m, 2H), 2.95-2.85(m, 1H), 2.83-2.71(m, 2H ), 2.20-2.11(m, 3H), 2.03-1.86(m, 6H), 1.69-1.66(m, 3H), 1.57-1.49(m, 4H), 1.47-1.44(m, 4H).
[0092] Example 8: Preparation of Compound SC-3
[0093]
[0094] Using int-3 and C3 as reactants, 4.3 mg of the final product SC-3 was prepared by the above general method. 1H NMR (500MHz, DMSO) δ11.09 (s, 1H), 8.16-8.02 (m, 1H), 7.84-7.72 (m, 1H), 7.60-7.56 (m, 1H), 7.11-7.07 (m, 1H), 7.0 4-7.00 (m, 1H), 6.79 (dd, J=16.5, 10.3Hz, 1H), 6.55-6.51 (m, 1H), 6.39-6.20 (m, 1H), 5.87-5.69 (m, 1H), 5.46-5.17 (m, 1H), 5.05 (dd, J=12.8, 5.4Hz, 1H), 4.08-3.91 (m, 1H), 3.71-3.54 (m, 2H), 3.16-3.09 (m, 2H), 2.93-2.80 (m, 6H), 2.65-2.55(m, 2H), 2.10-1.98(m, 3H), 1.95-1.86(m, 2H), 1.81-1.65(m, 4H), 1.61-1.50(m, 6H), 1.43-1.31(m, 7H).
[0095] Test Example 1: Triple Negative Breast Cancer Cell MDA-MB-436 Proliferation Inhibition Activity Detection Experiment
[0096] MDA-MB-436, a triple-negative breast cancer cell line with good growth status, was cultured at 2x10 3 The cells were seeded in a 48-well transparent cell culture plate at a density of 100 μL / mL and a volume of 180 μL / well. The 48-well plate was gently shaken to evenly distribute the cells at the bottom of the well and placed in an incubator overnight. The next day, 20 μL of compounds of different concentrations were added to the wells, so that the concentrations of the compounds after dilution of the culture medium were 50 μM and 25 μM (containing 1‰ DMSO), and two replicate wells were made for each compound concentration. The culture medium containing 1‰ DMSO was used as a negative control and the drugs were administered in parallel. On the 6th day, a 48-well plate was taken, 20 μL of CCK8 reagent was added to each well, and after incubation at 37°C for 2 hours, fluorescence quantitative detection was performed on the Cytation 5 multifunctional microplate reader. Finally, the data was imported into the Graphpad software to analyze the inhibition of cell proliferation at concentrations of 50 μM and 25 μM of the compound. The results are shown in Table 1.
[0097] Table 1 Proliferation inhibition activity of the compounds of the present invention on MDA-MB-436 cells
[0098]
[0099] As can be seen from Table 1, the compounds of the present invention can inhibit the proliferation activity of MDA-MB-436 cells, among which compounds SV-1 and SC-2 show outstanding inhibitory effects on the proliferation of triple-negative breast cancer cells.
[0100] Test Example 2: Experimental study on the detection of proliferation inhibition activity of thyroid cancer cell CAL-62
[0101] The thyroid cancer cell line CAL-62, which is in good growth condition, was cultured at 8x10 3 The cells were seeded in a 48-well transparent cell culture plate at a density of 100 μL / mL and a volume of 180 μL / well. The 48-well plate was gently shaken to evenly distribute the cells at the bottom of the well and placed in an incubator overnight. The next day, 20 μL of compounds of different concentrations were added to the wells, so that the concentrations of the compounds after dilution of the culture medium were 50 μM and 25 μM (containing 1‰ DMSO), and two replicate wells were made for each compound concentration. The culture medium containing 1‰ DMSO was used as a negative control and the drugs were administered in parallel. On the 6th day, a 48-well plate was taken, 20 μL of CCK8 reagent was added to each well, and after incubation at 37°C for 2 hours, fluorescence quantitative detection was performed on the Cytation 5 multifunctional microplate reader. Finally, the data was imported into the Graphpad software to analyze the inhibition of cell proliferation at concentrations of 50 μM and 25 μM of the compound. The results are shown in Table 2.
[0102] Table 2 Proliferation inhibition activity of the compounds of the present invention on CAL-62 cells
[0103]
[0104] It can be seen from the data in Table 2 that the compounds of the present invention can inhibit the proliferation activity of CAL-62 cells, among which compounds SV-1, SV-3 and SC-2 show outstanding thyroid cancer cell proliferation inhibition effects.
Claims
1. A compound represented by formula (I), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof; in, The linking group is -(L 1 ) n -(L 2 ) n -(L 3 ) n -(L 4 ) n -(L 5 ) n -; L 1 , L 2 , L 3 , L 4 , L 5 Each independently selected from: -CR L 2-, -O-, -S-, -NR L -、 -N=、=N-、-CR L =CR L -、-C≡C-、C 3-8 Cyclic hydrocarbon group, 3-8 membered heterocyclic hydrocarbon group, 4-8 membered cyclic ketone, 4-8 membered cyclic lactam, P(=O)R L 、P(=O)OR L ; Each n is independently selected from any integer between 0 and 20; Each RL is independently selected from H, halogen, -OH, -NH2, -SH, C 1-8 Alkyl, C 2-8 Olefin group, C 2-8 Alkyne, -O(C 1-8 Alkyl), -S(C 1-8 Alkyl), -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, -O(C 3-8 Cycloalkyl), -S(C 3-8 Cycloalkyl), -NH(C 3-8 Cycloalkyl), -N(C 3-8 -O(3-8 membered heterocyclic hydrocarbon group), -S(3-8 membered heterocyclic hydrocarbon group), -NH(3-8 membered heterocyclic hydrocarbon group), -N(C3-8 membered heterocyclic hydrocarbon group)2, -N(3-8 membered heterocyclic hydrocarbon group)(C 3-8 Cyclic hydrocarbon group), -N(3-8 membered heterocyclic hydrocarbon group)(C1-8 alkyl group), -N(C1-8 alkyl group)(C 3-8 wherein the heterocyclic hydrocarbon group contains 1 to 4 heteroatoms selected from N, O or S in the ring; The E3 ubiquitin ligase ligand is selected from:
2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof, characterized in that: In formula (I), The linking group is -(L 1 ) n -(L 2 ) n -(L 3 ) n -(L 4 ) n -(L 5 ) n -; Among them, L 1 , L 2 , L 3 , L 4 , L 5 Each independently selected from: -CR L 2-, -O-, -S-, -NR L -、 -N=、=N-、-CR L =CR L -、-C≡C-、P(=O)R L 、P(=O)OR L ; Each n is independently selected from any integer between 0 and 10, Each R L Each is independently selected from H, halogen, -OH, -NH2, -SH, C 1-8 Alkyl, C 2-8 Olefin group, C 2-8 Alkyne, -O(C 1-8 Alkyl), -S(C 1-8 Alkyl), -NH(C 1-8 Alkyl), -N(C 1-8 Alkyl)2.
3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof, characterized in that: In formula (I), The linking group is selected from -(CR L 2) n -, -(CR L 2) n -CO-, -CO-(CR L 2) n -, -(CR L 2) n -CONR L -, -NR L CO-(CR L 2) n -, -(CR L 2) n CONR L (CR L 2) n -, -(CR L 2) n NR L CO(CR L 2) n -, -(CR L 2) n CONR L (CR L 2) n CO-, -CO(CR L 2) n CONR L (CR L 2) n -, -(CR L 2) n -O-, -O-(CR L 2) n -, -(CR L 2-O) n -(CR L 2) n -, -(CR L 2) n -S-, -S-(CR L 2) n -, -NR L -(CR L 2) n -, -(CR L 2) n -NR L -; Wherein, each n is independently selected from any integer between 1 and 8; Each R L Each is independently selected from H, halogen, -OH, -NH2, -SH, C 1-8 alkyl.
4. The compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof, characterized in that: In formula (I), The linking group is selected from -(CR L 2) n -、-(CR L 2) n -CO-、-CO-(CR L 2) n -、-(CR L 2) n CONR L (CR L 2) n -、-(CR L 2) n NR L CO(CR L 2) n -、-(CR L 2) n CONR L (CR L 2) n CO-、-CO(CR L 2) n CONR L (CR L 2) n -; Wherein, each n is independently selected from any integer between 2 and 8; Each R L are independently H, halogen, -OH, -NH2, -SH, C 1-3 alkyl.
5. The compound of formula (I) according to claim 4, or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof, characterized in that: In formula (I), Each n is independently selected from any integer between 3 and 8; Each R L Each is independently H.
6. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof, characterized in that: The compound represented by formula (I) is selected from the following structures:
7. A c-Src kinase degrading agent, comprising the compound of formula (I) according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof.
8. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative thereof; and optionally, a pharmaceutically acceptable carrier.
9. Use of the compound of formula (I) according to any one of claims 1 to 6 or its pharmaceutically acceptable salt, geometric isomer, stereoisomer, prodrug, solvate or isotope-labeled derivative, or the pharmaceutical composition according to claim 8 in the preparation of a drug for treating, preventing and / or ameliorating diseases associated with c-Src kinase.
10. The use according to claim 9, characterized in that: The diseases associated with c-Src kinase include: cancer, cardiovascular disease, neurodegenerative disease, malaria, AIDS, gout, diabetes, renal failure, chronic lung disease; Preferably, the cancer comprises colon cancer, diffuse large B-cell lymphoma, follicular lymphoma, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast cancer, bile duct and gallbladder cancer, bladder cancer, brain tumor, neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancer, parathyroid tumors, uterine tumors and soft tissue sarcoma.
